Genomic Health, Inc. (NASDAQ:GHDX)

CAPS Rating: 5 out of 5

A life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Results 1 - 20 of 43 : 1 2 3 Next »

Recs

0
Member Avatar Tophinater (22.20) Submitted: 9/19/2014 12:01:12 AM : Outperform Start Price: $29.08 GHDX Score: +18.24

I don't know.

Recs

0
Member Avatar PatientJC (32.56) Submitted: 2/10/2014 11:40:55 AM : Outperform Start Price: $26.38 GHDX Score: +18.23

Superior fundamentals

Recs

0
Member Avatar legofkan1 (< 20) Submitted: 11/9/2013 11:07:35 AM : Outperform Start Price: $34.98 GHDX Score: -14.70

EXPANDING!

Recs

0
Member Avatar TerryHoodSr (64.97) Submitted: 7/29/2013 11:02:13 PM : Outperform Start Price: $31.99 GHDX Score: -12.97

growth

Recs

0
Member Avatar iksnamyzs (77.07) Submitted: 1/6/2013 1:10:27 PM : Outperform Start Price: $27.75 GHDX Score: -13.42

guy on dip

Recs

1
Member Avatar FoolishDane (< 20) Submitted: 11/20/2012 9:27:36 AM : Outperform Start Price: $26.83 GHDX Score: -15.99

A single treatment won't work for everyone, so there's definite promise in a company working to perfect tests so that individualized treatments may be prescribed. This would result in less frustration for the patient and his/her family and, hopefully, better survival rates.

Recs

0
Member Avatar TMFHumbleServant (97.51) Submitted: 11/20/2012 7:38:03 AM : Outperform Start Price: $26.83 GHDX Score: -15.99

Genomics will continue to play a bigger role in the future of medicine and treatments.

Recs

0
Member Avatar poinke (99.32) Submitted: 11/7/2012 11:45:04 AM : Outperform Start Price: $28.61 GHDX Score: -22.83

Strong insider buys & strength of colon/protate cancer tests could eliminate chemo. Long

Recs

0
Member Avatar clymerjones (59.16) Submitted: 9/5/2012 10:47:49 PM : Outperform Start Price: $35.36 GHDX Score: -43.40

There is no more important health issue than getting treatments right in the fight against cancer and GHDX has the best if those tools right now. I expect their research to continue and that should them keep them in a leadership position.

Recs

0
Member Avatar TMFBoiseKen (93.47) Submitted: 7/3/2012 12:49:33 PM : Outperform Start Price: $35.86 GHDX Score: -49.33

I'd love to get it a little cheaper, but I think it can outperform over 5-10 years from here.

Recs

0
Member Avatar pthammond (< 20) Submitted: 6/15/2010 6:59:21 PM : Outperform Start Price: $14.38 GHDX Score: +57.71

A whole new way to diagnose that has to catch on. With limited competition, this company will do well.

Recs

1
Member Avatar gt1135 (< 20) Submitted: 2/10/2010 9:49:51 AM : Outperform Start Price: $16.95 GHDX Score: +15.33

Sitting near 52 week low. It won't last. Wish I had more real $$ to invest in this one at the moment.

Recs

1
Member Avatar simonhs (< 20) Submitted: 2/9/2010 7:28:05 PM : Outperform Start Price: $17.09 GHDX Score: +13.41

Aging population, more and more cancer. Might as well make some money off it.

Recs

1
Member Avatar scoobamang (< 20) Submitted: 11/25/2009 10:52:00 PM : Outperform Start Price: $18.80 GHDX Score: -2.22

Revenue increasing at a very nice clip, about to climb out of the red and into profitability, nice cash cushion. Life science sounds sexy.

Recs

1
Member Avatar neilphipps (< 20) Submitted: 6/23/2009 4:31:02 PM : Outperform Start Price: $16.48 GHDX Score: -15.80

Genomics is a promising direction for genetic studies.

Recs

1
Member Avatar Cab53RobertMsnG (56.70) Submitted: 5/28/2009 2:12:13 PM : Outperform Start Price: $19.05 GHDX Score: -41.83

GHDX

Recs

1
Member Avatar jajex1 (72.94) Submitted: 5/12/2009 9:52:38 AM : Outperform Start Price: $19.66 GHDX Score: -46.83

fransgeraedts pick

Recs

6
Member Avatar zzlangerhans (99.80) Submitted: 5/10/2009 6:33:47 PM : Outperform Start Price: $20.17 GHDX Score: -48.62

Oncotype DX revenues for the last four quarters were 26, 28, 31 and 34 million respectively. The assay was also recently shown to be predictive of distant recurrence in colon cancer, although the market was apparently disappointed by its inability to predict the effectiveness of chemotherapy as it does in breast cancer. The company remains unprofitable as they aggressively pursue expanded indications for the Oncotype DX assay, but the burn rate is well controlled with a cash position that will carry them safely at least through the end of 2010 without dilution. Due to their reliance on a single product and lack of a clear pipeline, GH has an inherently weaker risk/reward profile when compared to Myriad. However, their current share price represents an attractive entry point given that they were at 27 a month ago without any change in fundamentals.

Recs

1
Member Avatar SmallPimpin (34.90) Submitted: 5/6/2009 8:14:03 PM : Outperform Start Price: $19.60 GHDX Score: -41.72

Mmm...medical tests...

Recs

1
Member Avatar jdwoollard (< 20) Submitted: 10/13/2008 6:12:51 PM : Outperform Start Price: $21.00 GHDX Score: -32.23

This company allows for targeted treatment of breast cancer. By better determining patients that will benefit from chemotherapy, there are substantial benefits for the patient and for the payors.

Results 1 - 20 of 43 : 1 2 3 Next »

Featured Broker Partners


Advertisement